Eisai Co. Ltd., of Tokyo, reported that Zonegran (zonisamide) was well tolerated and efficacious when used as an adjunctive treatment for partial epilepsy, with or without secondary generalization, in children between the ages of 6 and 17 for at least one year, according to results from a phase III study published in Epilepsia. Results also showed that the second-generation anti-epileptic was not associated with any unexpected safety issues or detrimental effects on children's growth and development.

Pfizer Inc., of New York, reported top-line data from two pivotal phase III trials from the OPT (Oral treatment Psoriasis Trials) program testing JAK inhibitor tofacitinib in moderate to severe plaque psoriasis. Data from the studies showed that tofacitinb, as a 5-mg or 10-mg dose taken as a pill twice daily, met the primary endpoints of statistically significant superiority over placebo at week 16 in the proportion of subjects achieving a Physician's Global Assessment response of "clear" or "almost clear," and the proportion of subjects achieving at least a 75 percent reduction in Psoriasis Area and Severity Index. Top-line data from the first two studies from the OPT program were disclosed last year and those four studies, plus data from a long-term extension study, will form the basis of a supplemental new drug application, expected to be submitted by early 2015.